175 related articles for article (PubMed ID: 25360799)
1. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
Liu L; Dong X
PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
[TBL] [Abstract][Full Text] [Related]
2. Heat shock protein 70 inhibitors suppress androgen receptor expression in LNCaP95 prostate cancer cells.
Kita K; Shiota M; Tanaka M; Otsuka A; Matsumoto M; Kato M; Tamada S; Iwao H; Miura K; Nakatani T; Tomita S
Cancer Sci; 2017 Sep; 108(9):1820-1827. PubMed ID: 28691182
[TBL] [Abstract][Full Text] [Related]
3. Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer.
Yadav SS; Li J; Stockert JA; O'Connor J; Herzog B; Elaiho C; Galsky MD; Tewari AK; Yadav KK
Oncotarget; 2016 Nov; 7(46):76181-76196. PubMed ID: 27783994
[TBL] [Abstract][Full Text] [Related]
4. Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.
Sugawara T; Nevedomskaya E; Heller S; Böhme A; Lesche R; von Ahsen O; Grünewald S; Nguyen HM; Corey E; Baumgart SJ; Georgi V; Pütter V; Fernández-Montalván A; Vasta JD; Robers MB; Politz O; Mumberg D; Haendler B
Mol Oncol; 2024 Mar; 18(3):726-742. PubMed ID: 38225213
[TBL] [Abstract][Full Text] [Related]
5. Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.
Ferraldeschi R; Welti J; Powers MV; Yuan W; Smyth T; Seed G; Riisnaes R; Hedayat S; Wang H; Crespo M; Nava Rodrigues D; Figueiredo I; Miranda S; Carreira S; Lyons JF; Sharp S; Plymate SR; Attard G; Wallis N; Workman P; de Bono JS
Cancer Res; 2016 May; 76(9):2731-42. PubMed ID: 27197266
[TBL] [Abstract][Full Text] [Related]
6. AR-v7 protein expression is regulated by protein kinase and phosphatase.
Li Y; Xie N; Gleave ME; Rennie PS; Dong X
Oncotarget; 2015 Oct; 6(32):33743-54. PubMed ID: 26378044
[TBL] [Abstract][Full Text] [Related]
7. Crosstalking between androgen and PI3K/AKT signaling pathways in prostate cancer cells.
Lee SH; Johnson D; Luong R; Sun Z
J Biol Chem; 2015 Jan; 290(5):2759-68. PubMed ID: 25527506
[TBL] [Abstract][Full Text] [Related]
8. Increased transcription and high translation efficiency lead to accumulation of androgen receptor splice variant after androgen deprivation therapy.
Ma T; Bai S; Qi Y; Zhan Y; Ungerleider N; Zhang DY; Neklesa T; Corey E; Dehm SM; Zhang K; Flemington EK; Dong Y
Cancer Lett; 2021 Apr; 504():37-48. PubMed ID: 33556543
[TBL] [Abstract][Full Text] [Related]
9. The role of mRNA splicing in prostate cancer.
Lapuk AV; Volik SV; Wang Y; Collins CC
Asian J Androl; 2014; 16(4):515-21. PubMed ID: 24830689
[TBL] [Abstract][Full Text] [Related]
10. Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers.
Zhang A; Lau NA; Wong A; Brown LG; Coleman IM; De Sarkar N; Li D; DeLucia DC; Labrecque MP; Nguyen HM; Conner JL; Dumpit RF; True LD; Lin DW; Corey E; Alumkal JJ; Nelson PS; Morrissey C; Lee JK
Cancer Res Commun; 2023 Nov; 3(11):2358-2374. PubMed ID: 37823778
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor splice variants and prostate cancer: From bench to bedside.
Wadosky KM; Koochekpour S
Oncotarget; 2017 Mar; 8(11):18550-18576. PubMed ID: 28077788
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.
De Velasco MA; Kura Y; Yoshikawa K; Nishio K; Davies BR; Uemura H
Oncotarget; 2016 Mar; 7(13):15959-76. PubMed ID: 26910118
[TBL] [Abstract][Full Text] [Related]
13. Alternations of gene expression in PI3K and AR pathways and DNA methylation features contribute to metastasis of prostate cancer.
Zhao Y; Hu X; Yu H; Liu X; Sun H; Shao C
Cell Mol Life Sci; 2022 Jul; 79(8):436. PubMed ID: 35864178
[TBL] [Abstract][Full Text] [Related]
14.
Choudhry M; Gamallat Y; Khosh Kish E; Seyedi S; Gotto G; Ghosh S; Bismar TA
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047027
[TBL] [Abstract][Full Text] [Related]
15. Caffeic acid phenethyl ester suppresses the expression of androgen receptor variant 7 via inhibition of CDK1 and AKT.
Kuo YY; Huo C; Li CY; Chuu CP
Cancer Gene Ther; 2024 Mar; ():. PubMed ID: 38480977
[TBL] [Abstract][Full Text] [Related]
16. CHRM4/AKT/MYCN upregulates interferon alpha-17 in the tumor microenvironment to promote neuroendocrine differentiation of prostate cancer.
Wen YC; Tram VTN; Chen WH; Li CH; Yeh HL; Thuy Dung PV; Jiang KC; Li HR; Huang J; Hsiao M; Chen WY; Liu YN
Cell Death Dis; 2023 May; 14(5):304. PubMed ID: 37142586
[TBL] [Abstract][Full Text] [Related]
17. Microbiome Dysbiosis Is Associated with Castration Resistance and Cancer Stemness in Metastatic Prostate Cancer.
Uzelac M; Xin R; Ongkeko WM
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542265
[TBL] [Abstract][Full Text] [Related]
18. Implications of PI3K/AKT inhibition on REST protein stability and neuroendocrine phenotype acquisition in prostate cancer cells.
Chen R; Li Y; Buttyan R; Dong X
Oncotarget; 2017 Oct; 8(49):84863-84876. PubMed ID: 29156689
[TBL] [Abstract][Full Text] [Related]
19. Integrated analysis identifies GABRB3 as a biomarker in prostate cancer.
Chen JY; Chang CF; Huang SP; Huang CY; Yu CC; Lin VC; Geng JH; Li CY; Lu TL; Bao BY
BMC Med Genomics; 2024 Jan; 17(1):41. PubMed ID: 38287309
[TBL] [Abstract][Full Text] [Related]
20. Minor intron splicing is critical for survival of lethal prostate cancer.
Augspach A; Drake KD; Roma L; Qian E; Lee SR; Clarke D; Kumar S; Jaquet M; Gallon J; Bolis M; Triscott J; Galván JA; Chen Y; Thalmann GN; Kruithof-de Julio M; Theurillat JP; Wuchty S; Gerstein M; Piscuoglio S; Kanadia RN; Rubin MA
Mol Cell; 2023 Jun; 83(12):1983-2002.e11. PubMed ID: 37295433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
